Skip to main content
. 2004 Feb 24;90(6):1190–1197. doi: 10.1038/sj.bjc.6601676

Table 1. Demographics and baseline characteristics.

  >Capecitabine 5-FU/LV
  (n=603) (n=604)
Male/female (%) 60/40 61/39
Age (years): median (range) 64 (23–86) 63 (24–87)
KPS (%): mean (range) 89 (70–100) 89 (70–100)
Colon/rectal cancer (%) 70/30 71/29
     
Tumour differentiation (%)    
 Well differentiated 11 11
 Moderately differentiated 62 63
 Poorly differentiated 19 17
 Undetermined/unknown  8 10
     
Number of metastatic sites (%)    
 1 25 22
 2 24 21
 ⩾3 52 57
     
Metastatic sites (%)    
 Liver 77 77
 Lung 33 33
 Lymph nodes 33 35
 Peritoneum 14 14
     
Prior adjuvant chemotherapy (%) 24 26